full issue - Association of Biotechnology and Pharmacy

Current Trends in Biotechnology and Pharmacy
Vol. 5 (3) 1251-1272 July 2011, ISSN 0973-8916 (Print), 2230-7303 (Online)
1268
converting enzyme, and endothelin
receptors in chronic heart failure.
Circulation, 99: 2118-2123
28. Kawanabe, Y.and Nauli, S. (2011).
Endothelin. Cellular and Molecular Life
Sciences, 68: 195-203.
29. Schiffrin, E.L. (2001). Role of endothelin-
1 in hypertension and vascular disease. Am
J Hypertens, 14: 83S-89S
30. Opgenorth, T.J. (1995). Endothelin receptor
antagonism. Adv Pharmacol, 33: 1-65.
31. Nakajima, S., Niiyama, K., Ihara, M.,
Kojiri, K. and Suda, H. (1991). Endothelinbinding
inhibitors, BE-18257A and BE-
18257B: II. Structure determination. J
Antibiot., 44: 1348-1356.
32. Ihara, M., Fukuroda, T., Saeki, T.,
Nishikibe, M., Kojiri, K., Suda, H. and
Yano, M. (1991). An endothelin receptor
(ET A
) antagonist isolated from
Streptomyces misakiensis. Biochem
Biophys Res Commun., 178: 132-137.
33. Ishikawa, K., Fukami, T., Nagase, T., Fujita,
K., Hayama, T., Niiyama, K., Mase, T.,
Ihara, M. and Yano, M. (1992). Cyclic
pentapeptide endothelin antagonists with
high ET A
selectivity. Potency and solubilityenhancing
modifications. J Med Chem., 35:
2139-2142.
34. Zuccarello, M., Lewis, A.I. and Rapoport,
R.M. (1994). Endothelin ET A
and ET B
receptors in subarachnoid haemorrhageinduced
cerebral vasospasm. Eur J
Pharmacol., 259: R1-R2.
35. Boss, C., Bolli, M. and Weller, T. (2002).
Endothelin receptor antagonists: structures,
synthesis, selectivity and therapeutic
applications. Current Medicinal Chemistry,
9: 349-383.
36. Mihara, S. and Fujimoto, M. (1993). The
endothelin ET A
receptor-specific effect of
50-235, a nonpeptide endothelin antagonist.
Eur J Pharmacol, 246: 33-38.
37. Zhang, R.L., Zhang, C., Zhang, L., Roberts,
C., Lu, M., Kapke, A., Cui, Y., Ninomiya,
M., Nagafuji, T., Albala, B., Zhang, Z.G.
and Chopp, M. (2008). Synergistic effect
of an endothelin type A receptor antagonist,
S-0139, with rtPA on the neuroprotection
after embolic stroke. Stroke, 39: 2830-
2836.
38. Elliot, J.D., Lago, M.A., Cousins, R.D.,
Gao, A., Leber, J.D., Erhard, K.F., Nambi,
P., Elshousbaby, N.A., Kumar, C., Lee, J.A.,
Bean, J.W., De Brosse, C.W., Eggleston,
D.S., Brooks, D.P., Beuerstein, G., Ruffolo,
R.R., Weinstock, J., Gleason, J.G., Peishoff,
C.E. and Ohlstein, E.H. (1994). 1,3-
Diarylindan-2-carboxylic acids, potent and
selective nonpeptide endothelin receptor
antagonists. J Med Chem., 37: 1553-1557.
39. Clozel, M., Breu, V., Gray, G., Kalina, B.,
Loffler, B.M., Burri, K., Cassal, J.M., Hirth,
G., Muller, M., Neidhart, W. and Ramuz,
H. (1994). Pharmacological
characterization of bosentan, a new potent
orally active nonpeptide endothelin
receptor antagonist. J Pharmacol Exp.
Ther., 270: 228-235.
40. Clozel, M., Breu, V., Burri, K., Cassal, J.M.,
Fischli, W., Gray, G.A., Hirth, G., Loffler,
B.M., Muller, M., Neidhart, W. and Ramuz,
H. (1993). Pathophysiological role of
endothelin revealed by the first orally active
endothelin receptor antagonist. Nature,
365: 759-761.
41. Clozel, M., Breu, V., Gray, G.A. and Loffler,
B.M. (1993). In vivo pharmacology of Ro
46-2005, the first synthetic nonpeptide
Does nature has the cure for hypertension